6 completed, 6 recruiting, 2 terminated, 2 unknown. 18 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 6, Recruiting 6, Terminated 2, Unknown 2, Withdrawn 2 |
| Phase 1 | 3 | Recruiting 2, Withdrawn 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Antiphospholipid Syndrome: new trials by email Literature Review of Antiphospholipid Syndrome trials Research Report on Antiphospholipid Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial) Anifrolumab - Antiphospholipid Syndrome (APS) | Phase 2 | Recruiting | National and Kapodistrian University of Athens | 20 | 2026-04-29 | 2026-06-02 |
| A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS) Crovalimab, Placebo, VKA - Antiphospholipid Syndrome | Phase 2 | Withdrawn | Hoffmann-La Roche | 2026-03-16 | 2026-03-02 | |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| Effect of Belimumab on Antibody Titers in Primary APS Patients Belimumab+SOC, SOC - Antiphospholipid Syndrome (APS) | Phase 2 | Recruiting | Ruijin Hospital | 20 | 2024-04-01 | 2024-12-24 |
| Effect of Telitacicept on Antibody Titers in Primary APS Patients Telitacicept+SOC, SOC - Antiphospholipid Syndrome (APS) | Phase 2 | Completed | Ruijin Hospital | 20 | 2023-12-01 | 2026-01-20 |
| Anti-CD38 Antibody Treating APS With Thrombocytopenia Anti-CD38 antibody Injection - Antiphospholipid Syndrome, Thrombocytopenia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2023-08-01 | 2025-08-05 |
| Daratumumab in Primary Antiphospholipid Syndrome Daratumumab - Autoimmune Disorders | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 22 | 2023-05-26 | 2026-10-21 |
| The BeLimumab Antiphospholipid Syndrome Trial (BLAST) Belimumab - Antiphospholipid Syndrome | Phase 2 / Phase 3 | Unknown | University of Turin, Italy | 15 | 2022-06-01 | 2023-01-13 |
| Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia zanubrutinib - Antiphospholipid Syndrome, Thrombocytopenia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2022-01-25 | 2025-02-24 |
| RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome Rivaroxaban, Warfarin - Antiphospholipid Syndrome, Systemic Lupus Erythematosus | Phase 2 | Completed | University College, London | 43 | 2021-07-09 | 2026-05-22 |
| Telitacicept in Primary APS Patients Telitacicept - Anti Phospholipid Syndrome | Phase 2 | Terminated | Peking Union Medical College Hospital | 20 | 2021-07-01 | 2025-06-08 |
| Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome Hydroxychloroquine, placebo - Antiphospholipid Syndrome (APS) | Phase 2 | Terminated | University Hospital, Rouen | 25 | 2016-05-17 | 2026-04-14 |
| Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome Eculizumab - Antiphospholipid Antibody Syndrome, End Stage Renal Disease | Phase 2 | Completed | Johns Hopkins University | 1 | 2009-11-01 | 2020-10-26 |
| Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients Fluvastatin - Antiphospholipid Syndrome | Phase 2 | Completed | Hospital for Special Surgery, New York | 41 | 2008-05-01 | 2018-05-01 |
| A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome Rituximab - Antiphospholipid Syndrome | Phase 2 | Completed | Hospital for Special Surgery, New York | 19 | 2007-09-01 | 2017-10-31 |
| Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome enoxaparin 40mg plus low dose aspirin, Heparin calcium5,000 U twice daily plus low dose aspirin - Recurrent Abortion | Phase 2 | Completed | Cairo University | 60 | 2006-06-01 | 2011-08-29 |
| Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss Low dose steroids - Antiphospholipid Syndrome | Phase 1 / Phase 2 | Withdrawn | Imperial College London | 2005-10-01 | 2024-02-26 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · Lupus Erythematosus, Systemic (2) · Myositis (2) · Scleroderma, Systemic (2) · Sjogren's Syndrome (2) · Thrombocytopenia (2) · Abortion, Habitual (1) · Autoimmune Diseases (1) · Behcet Syndrome (1) · Brain Ischemia (1) · Immunoglobulin G4-Related Disease (1) · Ischemic Stroke (1) · Kidney Failure, Chronic (1) · Purpura, Thrombotic Thrombocytopenic (1)
Immune System Diseases (18) · Autoimmune Diseases (17) · Blood Platelet Disorders (3) · Cardiovascular Diseases (3) · Connective Tissue Diseases (3) · Cytopenia (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Nervous System Diseases (3) · Skin and Connective Tissue Diseases (3) · Vascular Diseases (3) · Arthritis (2) · Arthritis, Rheumatoid (2) · Dry Eye Syndromes (2) · Eye Diseases (2)
Aspirin (1) · Enoxaparin (1) · Fluvastatin (1) · Hydroxychloroquine (1) · Rituximab (1) · Rivaroxaban (1) · Steroids (1) · Warfarin (1) · anifrolumab (1) · belimumab (1) · daratumumab (1) · eculizumab (1) · telitacicept (1) · zanubrutinib (1)
Hospital for Special Surgery, New York (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Ruijin Hospital (2) · Cairo University (1) · Hoffmann-La Roche (1) · Imperial College London (1) · Johns Hopkins University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National and Kapodistrian University of Athens (1) · Peking Union Medical College Hospital (1) · Peking University People's Hospital (1) · Peking University Third Hospital (1) · University College, London (1) · University Hospital, Rouen (1) · University of Turin, Italy (1)
China (7) · United States (4) · United Kingdom (2) · Egypt (1) · France (1) · Greece (1) · Italy (1)
Doruk Erkan, MD (2) · Lei Zhang, MD (2) · Ahmed M Sayed (1) · Benjamin Philosophe, MD, PHD (1) · Doruk Erkan, M.D., M.P.H. (1) · Hannah Cohen (1) · Jason Knight, M.D., Ph.D. (1) · Jiuliang Zhao, M.D. (1) · Raj Rai, MRCOG (1) · Silvia Pierangeli, PhD (1) · Usama M Fouda (1) · Zhanguo Li (1)
PMID 32358837, PMID 21251653, PMID 22269862, PMID 23124321
2025 (2), 2005 (1)